Elekta receives FDA clearance for Elekta Synergy (TM)

PRESS RELEASE

Stockholm, 28 October 2003 Images available - see below!

ELEKTA RECEIVES FDA CLEARANCE FOR ELEKTA SYNERGY(TM)

The revolutionary new radiotherapy system from Elekta is first to

combine x-ray volume imaging and treatment in a single platform

On Monday the 27 October, the U.S. Food and Drug Administration (FDA),

granted 510(k) pre-market clearance to the Elekta Synergy(TM) System

from Elekta. This means that Elekta can now market and sell the system

also in the U.S. In Europe, Elekta Synergy(TM) is already marketed,

following CE marking in July 2003.

In research and development over the last five years, this new

radiotherapy treatment platform directly addresses the two most

persistent and significant problems in modern radiation therapy:

internal organ motion and errors in patient set-up.

Elekta was the first vendor to start research on image-guided radiation

therapy, the first to have systems in clinical use, and the first to

bring these solutions to the market.

"With the introduction of Elekta Synergy(TM), Elekta is leading the

efforts to increase the precision of radiotherapy delivery by limiting

or even eliminating the impact of the patient's internal organ motion

and how the patient is set up for treatment from day to day", says Peter

J. Gaccione, vice president Oncology Sales and Service Operations for

Elekta North America.

Elekta Synergy(TM) does this by using innovative x-ray volume imaging

technology that is integrated directly onto the treatment system itself.

This means that routine pre-treatment imaging of a tumor can now be

performed immediately prior to treatment, decreasing the risk that a

tumor or internal organs will change position. In addition, since the

patient doesn't have to be moved from an imaging device (e.g. MR, CT) to

the radiotherapy treatment machine, the problem of errors from patient

re-setup are eliminated.

The first use of this new class of Image Guided Radiation Therapy (IGRT)

technology took place at the Netherlands Cancer Institute (NKI) in July

2003, when three cancer patients were treated using the Elekta

Synergy(TM) system. In addition to NKI, three other leading cancer

clinics in Great Britain, Canada and USA have research installations of

Elekta Synergy(TM).

Clinical data presented both at the recent ASTRO annual meeting in the

U.S. and the European ESTRO meeting, demonstrate the enormous potential

for the new Elekta Synergy(TM) system to significantly advance

radiotherapy treatment for cancer patients.

It has been shown that by combining an X-ray volume imaging system and

radiotherapy equipment (a medical accelerator) to provide 'real time'

images of the tumour during treatment, the image quality and treatment

accuracy is significantly improved. (ref:1,2)

Volker Stieber, Elekta's Executive Vice President - Technology

Development & Operations, acknowledged the aptness of the new product's

name, "Synergy is defined as two or more entities working together,

wherein the sum is greater than each individual's contribution. Elekta

Synergy(TM) adds dedicated imaging technology to a proven treatment

platform, creating a system that is truly more than the sum of its

parts."

******

Investor inquiries:

International: Peter Ejemyr, Group VP Corporate Communications, Elekta

AB (publ), Phone: +46 8 587 254 00, e-mail: peter.ejemyr@elekta.com

United States: Lars Jonsteg, VP Investor Relations North America,

Elekta, USA Phone: +1 770-670-2419, e-mail: lars.jonsteg@elekta.com

Press contact U.S:

Michelle Lee, PR and Advertising Manager

michelle.lee@elekta.com

Tel: +1 770-300-9725 x 277, Fax: +1 770-448-6338

Notes to editors:

· For further information regarding Elekta Synergy(TM) and other Elekta

products, please visit www.elekta.com

· Images of Elekta Synergy(TM) can be accessed at the following website

address: www.elekta.com/investors

*****